GLP-1 Medicaid coverage by US state

Generally yes — for type 2 diabetes. Ozempic is FDA-approved to treat type 2 diabetes, so most state Medicaid programs cover it for that diagnosis (usually with prior authorization). Medicaid does not routinely cover Ozempic for weight loss alone, because it is not FDA-approved for weight management — the weight-loss form of semaglutide is Wegovy.

Sometimes, but it is the exception. Wegovy is FDA-approved for chronic weight management, and as of 2026 only a minority of state Medicaid programs cover GLP-1s for weight loss — and where they do, it requires prior authorization (BMI thresholds, comorbidities, documented prior attempts). A federal proposal to require Medicaid and Medicare to cover anti-obesity medications remains unresolved, so coverage still varies by state. Check your state’s preferred-drug list or the tracker below.

Rarely, for the same reason as Wegovy. Zepbound (tirzepatide) is FDA-approved for weight management, and most state Medicaid programs do not cover GLP-1s for weight loss. Mounjaro — the same molecule approved for type 2 diabetes — is more often covered, but only for a diabetes diagnosis, not for weight loss.

A type 2 diabetes diagnosis. Medicaid coverage of GLP-1s is far broader for diabetes (Ozempic, Mounjaro) than for obesity (Wegovy, Zepbound). If you have diabetes, your prescriber may have more covered options. This is general information, not medical advice — only a licensed clinician can decide what to prescribe.

You have options: file an appeal (most state Medicaid programs allow internal and state-fair-hearing appeals with prescriber documentation of medical necessity), ask whether a diabetes-indicated option is covered, or compare cash-pay routes — compounded semaglutide/tirzepatide via telehealth starts around $69/month regardless of Medicaid status. Prices change; verify before buying.